Abstract
Ceftriaxone is a new semisynthetic cephalosporin with broad-spectrum in vitro activity and an unusually long serum half-life. The clinical efficacy of ceftriaxone was evaluated in 35 infections in 34 patients; 12 of these patients had skin and soft tissue infections, 10 had infections of the urinary tract, 8 had pneumonia, 2 had biliary tract infections, 1 had sinusitis, 1 had diverticulitis, and 1 had a retroperitoneal abscess. Of the 35 infections, 9 were bacteremic. The bacteria isolated included Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus faecalis, other streptococcal species, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Haemophilus influenzae, Pseudomonas aeruginosa, Bacteroides fragilis, other Bacteroides species, and anaerobic cocci. Improvement or cure occurred in 32 episodes, for a response rate of 91%. There were three treatment failures in patients with soft tissue infections. No serious drug toxicities were observed. At a dosage regimen of 1 g every 12 h the peak and trough serum antibiotic concentrations were well above the minimal inhibitory concentrations of most pathogens. Our findings suggest that ceftriaxone is a safe and effective antibiotic for therapy of serious bacterial infections.
Full text
PDF




Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Angehrn P., Probst P. J., Reiner R., Then R. L. Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies. Antimicrob Agents Chemother. 1980 Dec;18(6):913–921. doi: 10.1128/aac.18.6.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eickhoff T. C., Ehret J. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative. Antimicrob Agents Chemother. 1981 Mar;19(3):435–442. doi: 10.1128/aac.19.3.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fernex M., Havas L. Reports on cephtriaxone (Rocephin). Introduction and review. Chemotherapy. 1981;27 (Suppl 1):1–8. doi: 10.1159/000238020. [DOI] [PubMed] [Google Scholar]
- Hinkle A. M., Bodey G. P. In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother. 1980 Oct;18(4):574–578. doi: 10.1128/aac.18.4.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Keller R., Humair L. Treatment of severe lower respiratory tract infections with ceftriaxone (Ro 13-9904). A pilot study. Chemotherapy. 1981;27 (Suppl 1):93–99. doi: 10.1159/000238035. [DOI] [PubMed] [Google Scholar]
- Patel I. H., Miller K., Weinfeld R., Spicehandler J. Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy. 1981;27 (Suppl 1):47–56. doi: 10.1159/000238029. [DOI] [PubMed] [Google Scholar]
- Shannon K., King A., Warren C., Phillips I. In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases. Antimicrob Agents Chemother. 1980 Aug;18(2):292–298. doi: 10.1128/aac.18.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stoeckel K. Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy. 1981;27 (Suppl 1):42–46. doi: 10.1159/000238028. [DOI] [PubMed] [Google Scholar]
- Verbist L., Verhaegen J. In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother. 1981 Feb;19(2):222–225. doi: 10.1128/aac.19.2.222. [DOI] [PMC free article] [PubMed] [Google Scholar]